Business
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST SAN DIEGO--(BUSINESS WIRE)-- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"\n Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nLENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that the Company will host a conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results from its Phase 3 CLARITY study, a group of three multi-center, double-masked, randomized active and vehicle-controlled clinical trials evaluating the efficacy and safety of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia.\n\n\nConference Call and Webcast Event\nThe Company will host a conference call and webcast tomorrow, Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results. The live webcast and materials from the conference call can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section or by calling 877-315-3033 or 215-268-9883. A replay of the webcast will be archived and available for 30 days following the event.\n\n\nAbout LENZ Therapeutics\nLENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase 3 CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.\n\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expec...